Sabby Management, LLC Fibrogen Inc Transaction History

Sabby Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$37.09 - $48.97 $1.1 Million - $1.45 Million	-29,654 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$40.47 - $45.5 $158,075 - $177,723	-3,906 Reduced 11.64%	29,654 $1.22 Million
Q2 2020 Aug 14, 2020	BUY	$32.57 - $42.83 $1.09 Million - $1.44 Million	33,560 New	33,560 $1.36 Million
Q2 2019 Aug 14, 2019	SELL	$35.13 - $55.53 $463,540 - $732,718	-13,195 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$42.83 - $59.91 $1.38 Million - $1.93 Million	-32,222 Reduced 70.95%	13,195 $717,000
Q4 2018 Feb 14, 2019	BUY	$37.97 - $60.16 $1.27 Million - $2.01 Million	33,398 Added 277.88%	45,417 $2.1 Million
Q3 2018 Nov 14, 2018	BUY	$56.3 - $67.25 $85,970 - $102,690	1,527 Added 14.55%	12,019 $730,000
Q2 2018 Aug 14, 2018	BUY	$44.9 - $64.95 $471,090 - $681,455	10,492 New	10,492 $657,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Sabby Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sabby Management, LLC with notifications on news.